Lilly, Boehringer hit heart safety mark with Januvia rival Tradjenta. Is that enough?

Boehringer Ingelheim and Eli Lilly’s Tradjenta is working to pick up share in an ultracompetitive diabetes market, and it’s hoping some new outcomes data can help it do exactly that.